Filing Flows › Adaptive Biotechnologies (ADPT) › Q2 2026 › vs Q1 2026
Adaptive Biotechnologies (ADPT) Q2 2026 vs Q1 2026 (quarter over quarter)
Adaptive Biotechnologies's revenue rose $679K (+1%) from $70.9M in Q1 2026 to $71.6M in Q2 2026.
Adaptive Biotechnologies, Q2 2026: revenue $71.6M (+22% year over year), operating margin -22.0%, net loss $39.9M, operating cash flow −$6.4M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $71.6M | $70.9M | $679K | +1% |
| Net loss | $39.9M | $20.0M | $19.9M | +100% |
| Costs & expenses | $111M | $90.9M | $20.6M | +23% |
| Operating costs | $87.3M | $90.1M | −$2.8M | -3% |
| Interest & other, net | $24.2M | $809K | $23.4M | 30× |
| Cost of revenue | $20.2M | $18.7M | $1.5M | +8% |
| Research & development | $19.2M | $23.6M | −$4.5M | -19% |
| Sales & marketing | $26.4M | $26.3M | $68K | +0.3% |
| General & admin | $21.2M | $21.0M | $184K | +0.9% |
| Other operating costs | $423K | $419K | $4K | +1% |
| Operating cash sources | $39.9M | $20.0M | $19.9M | +100% |
| Depreciation & amortization | $3.7M | $3.4M | $309K | +9% |
| Share-based compensation | $11.1M | $11.9M | −$809K | -7% |
| Working capital & other | $18.7M | −$4.8M | $23.6M | — |
| Cash used in operations | $6.4M | $9.5M | −$3.1M | -33% |
| Net loss absorbed | $39.9M | $20.0M | $19.9M | +100% |
Questions
How much did Adaptive Biotechnologies's revenue grow quarter over quarter in Q2 2026?
Adaptive Biotechnologies's revenue rose $679K (+1%) from $70.9M in Q1 2026 to $71.6M in Q2 2026.